Comparison of CD34+ cell number in patients with different types of Philadelphia-negative chronic myeloproliferative disorders and according clinical parameters
| Disease type . | No. cases . | Median CD34+ cells, × 106/L (range) . |
|---|---|---|
| MMM (all patients) | 84 | 91.6 (0-2460) |
| MMM (primary) | 65 | 301.9 (0-2460) |
| MMM (post-PV or post-ET) | 19 | 147.2 (18.3-556.2) |
| MMM (had had a splenectomy) | 8 | 616.0 (4.3-2460) |
| MMM (had not had a splenectomy) | 76 | 232.0 (0-1789) |
| MMM (under cytotoxic therapy) | 17 | 391.0 (0-1789) |
| MMM (out of cytotoxic therapy) | 67 | 235.5 (2.04-2460) |
| PV | 6 | 5.0 (4.4-10) |
| ET | 6 | 6.0 (3.1-26.9) |
| AMD | 8 | 5.0 (3.7-15.5) |
| Healthy controls | 21 | 0.25 (0.15-0.35) |
| Disease type . | No. cases . | Median CD34+ cells, × 106/L (range) . |
|---|---|---|
| MMM (all patients) | 84 | 91.6 (0-2460) |
| MMM (primary) | 65 | 301.9 (0-2460) |
| MMM (post-PV or post-ET) | 19 | 147.2 (18.3-556.2) |
| MMM (had had a splenectomy) | 8 | 616.0 (4.3-2460) |
| MMM (had not had a splenectomy) | 76 | 232.0 (0-1789) |
| MMM (under cytotoxic therapy) | 17 | 391.0 (0-1789) |
| MMM (out of cytotoxic therapy) | 67 | 235.5 (2.04-2460) |
| PV | 6 | 5.0 (4.4-10) |
| ET | 6 | 6.0 (3.1-26.9) |
| AMD | 8 | 5.0 (3.7-15.5) |
| Healthy controls | 21 | 0.25 (0.15-0.35) |
MMM indicates myelofibrosis with myeloid metaplasia; PV, polycythemia vera; ET, essential thrombocythemia; AMD, atypical myeloproliferative disorder.